Lengfelder, Eva and Haferlach, C. and Saussele, S. and Haferlach, T. and Schultheis, B. and Schnittger, S. and Ludwig, W-D and Staib, P. and Aul, C. and Grueneisen, A. and Kern, W. and Reichle, A. and Serve, H. and Berdel, W. E. and Braess, J. and Spiekermann, K. and Woermann, B. and Sauerland, M-C and Heinecke, A. and Hiddemann, W. and Hehlmann, R. and Buechner, T. (2009) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. LEUKEMIA, 23 (12). pp. 2248-2258. ISSN 0887-6924, 1476-5551
Full text not available from this repository. (Request a copy)Abstract
The objective of this study for newly diagnosed acute promyelocytic Leukemia (APL) was to evaluate the efficacy of an intensified double induction chemotherapy including high dose ara-C (HD) and all-trans retinoic acid (ATRA) followed by consolidation and 3 years maintenance therapy. In contrast to APL studies stratifying therapy according to pretreatment white blood cell (WBC) count < and >= 10 x 10(9)/l (low/intermediate and high risk according to the Sanz score), our patients received uniform therapy. From 1994 to 2005, 142 patients (age, 16-60 years) were enrolled. In the low/intermediate (n = 105) vs high (n = 37) WBC group, the rates of complete remission were 95.2 vs 83.8%, of induction death were 4.8 vs 16.2% (P = 0.05) and of molecular remission were 87.5 vs 91.3% (P = 1). Long-term overall survival was 84.4 vs 73.0% (P = 0.12), event free survival was 78.3 vs 67.3% (P = 0.11), relapse free survival was 82.1 vs 80.0% (P = 0.83) and the cumulative incidence of relapse was 7.4 vs 11.4% (P = 0.46). No relapse or death occurred after 4.7 years. ATRA and intensified chemotherapy including HD ara-C followed by prolonged maintenance therapy reduced the relapse risk in high risk patients. Pretreatment WBC count >= 10 x 10(9)/l count was no relevant prognostic factor for relapse. Leukemia (2009) 23, 2248-2258; doi:10.1038/leu.2009.183; published online 10 September 2009
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | TRANS-RETINOIC ACID; ACUTE MYELOID-LEUKEMIA; DOUBLE INDUCTION STRATEGY; REMISSION INDUCTION; RANDOMIZED-TRIAL; MYELODYSPLASTIC SYNDROME; CYTOSINE-ARABINOSIDE; TRANSRETINOIC ACID; PROGNOSTIC-FACTORS; CHEMOTHERAPY; acute promyelocytic leukemia; high dose cytosine arabinoside; relapse rate; white blood cell count |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 31 Aug 2020 09:30 |
| Last Modified: | 31 Aug 2020 09:30 |
| URI: | https://pred.uni-regensburg.de/id/eprint/28065 |
Actions (login required)
 |
View Item |
